Antiviral function and viral antagonism of the rapidly evolving dynein activating adaptor NINL.

dynein host–virus evolution human immunology infectious disease inflammation innate antiviral immunity microbiology microtubule-based transport viral antagonist viral protease viruses

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
12 10 2022
Historique:
received: 04 07 2022
accepted: 11 10 2022
pubmed: 13 10 2022
medline: 16 11 2022
entrez: 12 10 2022
Statut: epublish

Résumé

Viruses interact with the intracellular transport machinery to promote viral replication. Such host-virus interactions can drive host gene adaptation, leaving signatures of pathogen-driven evolution in host genomes. Here, we leverage these genetic signatures to identify the dynein activating adaptor, ninein-like (NINL), as a critical component in the antiviral innate immune response and as a target of viral antagonism. Unique among genes encoding components of active dynein complexes, NINL has evolved under recurrent positive (diversifying) selection, particularly in its carboxy-terminal cargo-binding region. Consistent with a role for NINL in host immunity, we demonstrate that NINL knockout cells exhibit an impaired response to interferon, resulting in increased permissiveness to viral replication. Moreover, we show that proteases encoded by diverse picornaviruses and coronaviruses cleave and disrupt NINL function in a host- and virus-specific manner. Our work reveals the importance of NINL in the antiviral response and the utility of using signatures of host-virus genetic conflicts to uncover new components of antiviral immunity and targets of viral antagonism. Humans and viruses are locked in an evolutionary arms race. Viruses hijack cells, using their resources and proteins to build more viral particles; the cells fight back, calling in the immune system to fend off the attack. Both actors must constantly and quickly evolve to keep up with each other. This genetic conflict has been happening for millions of years, and the indelible marks it has left on genes can serve to uncover exactly how viruses interact with the organisms they invade. One hotspot in this host-virus conflict is the complex network of molecules that help to move cargo inside a cell. This system transports elements of the immune system, but viruses can also harness it to make more of themselves. Scientists still know very little about how viruses and the intracellular transport machinery interact, and how this impacts viral replication and the immune response. Stevens et al. therefore set out to identify new interactions between viruses and the transport system by using clues left in host genomes by evolution. They focused on dynein, a core component of this machinery which helps to haul molecular actors across a cell. To do so, dynein relies on adaptor molecules such as 'Ninein-like', or NINL for short. Closely examining the gene sequence for NINL across primates highlighted an evolutionary signature characteristic of host-virus genetic conflicts; this suggests that the protein may be used by viruses to reproduce, or by cells to fend off infection. And indeed, human cells lacking the NINL gene were less able to defend themselves, allowing viruses to grow much faster than normal. Further work showed that NINL was important for a major type of antiviral immune response. As a potential means to sabotage this defence mechanism, some viruses cleave NINL at specific sites and disrupt its role in intracellular transport. Better antiviral treatments are needed to help humanity resist old foes and new threats alike. The work by Stevens et al. demonstrates how the information contained in host genomes can be leveraged to understand what drives susceptibility to an infection, and to pinpoint molecular actors which could become therapeutic targets.

Autres résumés

Type: plain-language-summary (eng)
Humans and viruses are locked in an evolutionary arms race. Viruses hijack cells, using their resources and proteins to build more viral particles; the cells fight back, calling in the immune system to fend off the attack. Both actors must constantly and quickly evolve to keep up with each other. This genetic conflict has been happening for millions of years, and the indelible marks it has left on genes can serve to uncover exactly how viruses interact with the organisms they invade. One hotspot in this host-virus conflict is the complex network of molecules that help to move cargo inside a cell. This system transports elements of the immune system, but viruses can also harness it to make more of themselves. Scientists still know very little about how viruses and the intracellular transport machinery interact, and how this impacts viral replication and the immune response. Stevens et al. therefore set out to identify new interactions between viruses and the transport system by using clues left in host genomes by evolution. They focused on dynein, a core component of this machinery which helps to haul molecular actors across a cell. To do so, dynein relies on adaptor molecules such as 'Ninein-like', or NINL for short. Closely examining the gene sequence for NINL across primates highlighted an evolutionary signature characteristic of host-virus genetic conflicts; this suggests that the protein may be used by viruses to reproduce, or by cells to fend off infection. And indeed, human cells lacking the NINL gene were less able to defend themselves, allowing viruses to grow much faster than normal. Further work showed that NINL was important for a major type of antiviral immune response. As a potential means to sabotage this defence mechanism, some viruses cleave NINL at specific sites and disrupt its role in intracellular transport. Better antiviral treatments are needed to help humanity resist old foes and new threats alike. The work by Stevens et al. demonstrates how the information contained in host genomes can be leveraged to understand what drives susceptibility to an infection, and to pinpoint molecular actors which could become therapeutic targets.

Identifiants

pubmed: 36222652
doi: 10.7554/eLife.81606
pii: 81606
pmc: PMC9651953
doi:
pii:

Substances chimiques

Dyneins EC 3.6.4.2
Antiviral Agents 0

Banques de données

GEO
['GSE206784']

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM133633
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007240
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Informations de copyright

© 2022, Stevens, Beierschmitt et al.

Déclaration de conflit d'intérêts

DS, CB, SM, MC, JS, BT, BC, AR, HH, MD No competing interests declared, SR Reviewing editor, eLife

Références

Cilia. 2012 Apr 25;1(1):2
pubmed: 23351521
J Cell Biol. 2019 May 6;218(5):1619-1633
pubmed: 30814157
Nature. 2022 Oct;610(7930):212-216
pubmed: 36071160
Elife. 2022 Jun 15;11:
pubmed: 35703493
PLoS Genet. 2015 Oct 20;11(10):e1005574
pubmed: 26485514
Elife. 2022 Oct 12;11:
pubmed: 36222652
J Virol. 2003 Nov;77(21):11555-62
pubmed: 14557641
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
Nat Rev Immunol. 2012 Oct;12(10):687-95
pubmed: 22976433
Science. 2015 Mar 27;347(6229):1441-1446
pubmed: 25814576
Elife. 2016 May 31;5:
pubmed: 27240734
EMBO J. 2014 Sep 1;33(17):1855-68
pubmed: 24986880
Trends Microbiol. 2005 Jul;13(7):320-7
pubmed: 15950476
Curr Opin Microbiol. 2016 Aug;32:113-119
pubmed: 27288760
Genome Biol. 2014;15(12):550
pubmed: 25516281
Elife. 2021 Jan 07;10:
pubmed: 33410748
Nature. 1996 Aug 29;382(6594):822-6
pubmed: 8752278
FEBS Lett. 2017 Oct;591(20):3190-3210
pubmed: 28850669
Elife. 2017 Jul 18;6:
pubmed: 28718761
Front Immunol. 2021 Nov 01;12:769543
pubmed: 34790204
Genes Dev. 2013 Jun 1;27(11):1233-46
pubmed: 23723415
J Cell Biol. 1997 Jul 14;138(1):131-42
pubmed: 9214387
Nat Cell Biol. 2020 May;22(5):518-525
pubmed: 32341549
Biochem Biophys Res Commun. 2015 May 1;460(2):451-6
pubmed: 25796327
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
J Virol. 2020 Jan 6;94(2):
pubmed: 31666382
Nat Commun. 2020 Nov 10;11(1):5695
pubmed: 33173051
Mol Biol Evol. 2005 May;22(5):1208-22
pubmed: 15703242
Elife. 2016 May 17;5:
pubmed: 27187613
Nature. 2010 Nov 18;468(7322):452-6
pubmed: 21085181
Mol Biol Evol. 2007 Aug;24(8):1586-91
pubmed: 17483113
Biophys J. 2010 Oct 6;99(7):2143-52
pubmed: 20923648
Science. 2014 Jul 18;345(6194):337-41
pubmed: 25035494
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Curr Biol. 2017 Apr 24;27(8):R318-R326
pubmed: 28441569
J Cell Sci. 2019 Mar 15;132(6):
pubmed: 30877148
Virology. 2002 Sep 15;301(1):64-80
pubmed: 12359447
J Cell Biol. 2017 Oct 2;216(10):3051-3060
pubmed: 28883039
Nature. 2014 Jan 30;505(7485):691-5
pubmed: 24284630
Int Rev Cytol. 2000;192:189-221
pubmed: 10553280
Annu Rev Genet. 2012;46:677-700
pubmed: 23145935
Nucleic Acids Res. 2016 Jul 8;44(W1):W272-6
pubmed: 27185894
Nat Rev Immunol. 2016 Jan;16(1):7-21
pubmed: 26655628
Nat Rev Immunol. 2015 Sep 15;15(9):559-73
pubmed: 26292640
Mol Biol Evol. 2018 Mar 1;35(3):773-777
pubmed: 29301006
Biomedicines. 2021 Jul 01;9(7):
pubmed: 34356829
EMBO J. 2011 Aug 31;30(17):3527-39
pubmed: 21878994
Cell. 2018 Oct 4;175(2):360-371.e13
pubmed: 30290142
Trends Immunol. 2015 Mar;36(3):124-38
pubmed: 25704559
Nat Rev Mol Cell Biol. 2018 Jun;19(6):382-398
pubmed: 29662141
Annu Rev Virol. 2019 Sep 29;6(1):567-584
pubmed: 31283436
PLoS Genet. 2012;8(7):e1002764
pubmed: 22807683
Signal Transduct Target Ther. 2021 Apr 16;6(1):152
pubmed: 33859171
Rev Med Virol. 2021 Sep;31(5):1-22
pubmed: 33624382
J Cell Biol. 2021 Jul 5;220(7):
pubmed: 34014261
Immunity. 2018 Mar 20;48(3):487-499.e5
pubmed: 29525521
PLoS Genet. 2015 Oct 20;11(10):e1005575
pubmed: 26485645
Nat Commun. 2021 Jul 28;12(1):4578
pubmed: 34321481
Cell Microbiol. 2006 Mar;8(3):387-400
pubmed: 16469052
Curr Opin Cell Biol. 2021 Aug;71:69-76
pubmed: 33706236
Annu Rev Immunol. 2022 Apr 26;40:271-294
pubmed: 35080919
Dev Cell. 2003 Jul;5(1):113-25
pubmed: 12852856
Mol Immunol. 2019 Jul;111:73-82
pubmed: 31035111
Trends Microbiol. 2011 Jun;19(6):286-94
pubmed: 21531564
Nat Rev Microbiol. 2007 Mar;5(3):197-208
pubmed: 17304249
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Front Oncol. 2022 May 26;12:883301
pubmed: 35719990
Trends Microbiol. 2020 Jan;28(1):46-56
pubmed: 31597598
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
EMBO J. 2021 Apr 15;40(8):e106164
pubmed: 33734450
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Hum Mol Genet. 2009 Jan 1;18(1):51-64
pubmed: 18826961
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
mSphere. 2019 Feb 20;4(1):
pubmed: 30787120

Auteurs

Donté Alexander Stevens (DA)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States.

Christopher Beierschmitt (C)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

Swetha Mahesula (S)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States.
Howard Hughes Medical Institute, Chevy Chase, United States.

Miles R Corley (MR)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

John Salogiannis (J)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States.

Brian V Tsu (BV)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

Bryant Cao (B)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

Andrew P Ryan (AP)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

Hiroyuki Hakozawki (H)

Nikon Imaging Center at UC San Diego, University of California, San Diego, San Diego, United States.

Samara L Reck-Peterson (SL)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, United States.
Howard Hughes Medical Institute, Chevy Chase, United States.
Department of Cell and Developmental Biology, University of California, San Diego, La Jolla, United States.

Matthew D Daugherty (MD)

Department of Molecular Biology, University of California, San Diego, La Jolla, United States.

Articles similaires

Animals Swine Antiviral Agents Swine Diseases Coronavirus Infections
Humans Carcinoma, Hepatocellular Liver Neoplasms Aged United States

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin
1.00
Animals Mice Immunity, Innate Interneurons Synapses

Classifications MeSH